Spotlight on Nursing Leader Dr. Lindsay Jibb: Pediatric Oncology Research Trailblazer
Dr. Lindsay Jibb’s work is grounded in real-world challenges witnessed firsthand at the bedside. Currently, she leads research in several key areas: improving pain outcomes for children with cancer, supporting parents managing their child’s care at home, and addressing the psychosocial needs of children with cancer and their families. At the core of it all is a strong commitment to patient- and family-centred research.
Every study includes patients, survivors, or family members as research partners — not just as participants.
“It’s not even an option anymore to exclude those voices,” says Dr. Jibb. “They are integral to generating meaningful questions, ensuring the research is practical, and helping us share results in ways that matter.” This dedication to patient-and-family-centred research is now being integrated into my own doctoral work, which looks at parent perspectives of decision-making about enrollment in clinical trials.
For Dr. Jibb, research has always been a central passion — one that has evolved into a dynamic and impactful career at SickKids and the University of Toronto, where she’s leading transformative work in pediatric oncology nursing.
Dr. Jibb’s path to research began as she completed her undergraduate degree in biology, which gave her early exposure to research through a thesis project. That experience sparked a love for scientific inquiry, leading to the pursuit of her master’s degree in biochemistry though her heart always remained in healthcare. When she later entered nursing school, she knew she wanted to blend her clinical training with her research background.
“I always knew I would involve research somehow,” she explains. “It was a chance to take all the learning we do as nurses — clinical, theoretical, and practical — and use it to directly improve care for patients and families.”
When Dr. Jibb was offered the opportunity to pursue her doctoral degree with Dr. Jennifer Stinson, she jumped, and has been leading innovative pediatric oncology nursing research since.
Unlike her earlier experiences in lab-based science, Dr. Jibb found nursing research to be deeply collaborative and community-oriented.
“As a PhD student, I felt so supported by the nurses, managers, and colleagues on the unit. It felt like we were all working together, and that sense of shared purpose really stuck with me.” As an educator and mentor, Dr. Jibb is passionate about building a pipeline for future nurse researchers. She is an incredible role model, actively demonstrating how nurses can take their bedside experience and employ it in a scientist role to improve experience and outcomes for patients.
“I always say, ‘my door is open,’” she laughs. “If you’re a nurse interested in research, I’ll review your CV, talk about school, or help you find a way in.” Looking ahead, Dr. Jibb is excited about the growing recognition of nursing research in Canada. “It’s an exciting time. Organizations like POGO are investing in this work, and the next generation of nurse researchers is full of energy and fresh ideas.”
For Dr. Jibb, the reward from her research is clear. “When a patient or parent comes back and says, ‘thank you,’ to know that the work we’re doing matters to those people that we’re doing it for makes it all worth it.”
This story was written for the fall 2025 issue of The RePORTer, POGO’s Nursing Newsletter by: Rachel Hamilton, RN, MN, PhD(s), PhD Student and RN – 8A Inpatient Haematology/Oncology at SickKids
Nominated by Rachel, Dr. Jibb is the winner of the 2025 POGO Nursing Leadership Award. Rachel considers it a privilege to work under Dr. Jibb’s mentorship. From their first meeting, Dr. Jibb’s passion for research and dedication to improving patient care stood out. Her warmth, intelligence, and commitment to nurturing emerging nurse researchers create an exceptional training environment. Bridging clinical practice and scientific inquiry, Dr. Jibb serves as a role model for students like Rachel. This spotlight draws from Rachel’s interview with Dr. Jibb, highlighting her inspiring journey, impactful research, and contributions to pediatric oncology nursing. Her story is both motivating and enlightening, offering a glimpse into the dedication and passion required to transform patient care through nursing research.
Using AI for Brain Tumour Treatment
Radiation therapy (RT) is a common treatment for brain tumours (the second most common cancer in childhood after leukemia). The goal is to deliver a focused dose of radiation to the tumour and surrounding at-risk regions while minimizing radiation to normal brain tissues. This is particularly crucial for young patients in whom excess RT to normal brain tissues can lead to significant long-term side effects.
The standard method of manual radiation therapy planning is time-consuming and can vary in quality depending on the experience of the radiation therapist and oncology staff. Artificial intelligence (AI)-assisted planning has been shown to improve the speed and quality of RT plan design and reduce unnecessary doses to normal brain tissues.
In a project involving the Princess Margaret Cancer Centre in Toronto, as well as the London Regional Cancer Program (Ontario), researchers evaluated the potential benefit of collaborative AI-RT planning for children, youth and young adults with brain tumours. The group intends to disseminate the cutting-edge AI technology and create new collaborations to improve RT for thousands of cancer patients across Canada.
For this study, 61 patients were enrolled, with approximately two RT plans created by expert RT planners (standard practice) and one AI-assisted plan created for each patient. In a blind evaluation by the treating oncologists, the AI-assisted plans were deemed to be as good or better than the manual plans. AI-assisted plans delivered a slightly smaller dose of radiation to normal brain tissues and were designed in less time.
The conclusion: AI-assisted radiation therapy planning creates high-quality radiotherapy plans for children and young adults with brain tumours. This is the first study of AI-assisted RT planning to include children, and creates an opportunity to rapidly create high quality plans for patients needing urgent treatment, and facilitate planning for smaller centres.
Read the full published article: A Prospective Study of Machine Learning − Assisted Radiation Therapy Planning for Patients Receiving 54 Gy to the Brain
Derek S. Tsang, MD, MSc; Grace Tsui, BSc, MRT(T); Anna T. Santiago, MSc, MPH; Harald Keller, PhD; Thomas Purdie, PhD, FAAPM; Chris Mcintosh, PhD; Glenn Bauman, MD; Nancy La Macchia, MRT(T); Amy Parent, BSc, MRT(T); Hitesh Dama, BSc, MRT(T); Sameera Ahmed, MSc; Normand Laperriere, MD; Barbara-Ann Millar, MBChB; Valerie Liu, BSc; David C. Hodgson, MD, MPH, FASTRO
Study Examines Late Effects and Treatment Protocols for Hodgkin Lymphoma in Children
Childhood cancer and its treatment come at a risk of late effects for survivors. In fact, the evidence shows that two of every three childhood cancer survivors are at increased risk of at least one late effect due to their cancer or its treatment, including heart disease, second cancers and cognitive challenges.
A recent study published in JAMA (The Journal of the American Medical Association) looks at the treatment of Hodgkin lymphoma in children and the resulting risk of cardiac disease to survivors.
POGO Medical Director, Dr. David Hodgson, is the lead author of the study titled Late Cardiac Toxic Effects and Treatment Protocols for Hodgkin Lymphoma in Children.
“Cardiac disease as a late effect of treating Hodgkin lymphoma is a serious risk that is well documented,” he says. “One of the challenges of improving treatment is that we don’t want to wait for over 20 years to observe the late effects of treatments we’re currently giving today. The goal of this study was to estimate the risk of late effects of current treatment to better understand how to advise current patients and families, and also explore what changes to treatment would have the greatest benefit to reduce these risks.”
Understanding the extent to which treatment can be modified for improved health outcomes is critical for several reasons.
- Reducing treatment intensity is a trade-off against the risk of relapse.
- Understanding which components of treatment can be adjusted, and to what extent, can lead to better decisions about treatment modifications.
- Care for survivors is based on their treatment exposure making the burden of follow-up care an important consideration.
The study evaluated the treatment of 2,563 patients with Hodgkin lymphoma treated in four consecutive Children’s Oncology Group clinical trials between 2002 and 2022. Patients were treated with different doses of radiation therapy and doxorubicin chemotherapy – both of which are known to increase the risk of cardiac late effects. Based on the doses of these treatments, the 30-year cumulative incidence of severe or life-threatening heart disease was estimated to decrease from 10% in the first trial to 6% in the last trial. The findings were favourable, suggesting that evolutions in treating Hodgkin lymphoma will lead to a net reduction in late cardiac disease. Moreover, findings suggest that for adolescent and young adult patients, increasing the use of “cardioprotective” medications during treatment would be one of the best ways to reduce this risk further, without compromising cure rates.
“While there is still work to be done to monitor the long-term gains in reducing cardiac toxic effects, this is encouraging news that bodes well for the quality of life of childhood cancer survivors,” says Dr. Hodgson. “And, as with every study, we need to ensure that the guidelines for follow-up care of survivors, particularly in POGO AfterCare Clinics, are updated to reflect the latest evidence.”
Read the study here.
Related Content
How Slushies and Red Lights Provide Supportive Care for Childhood Cancer Patients
About a decade ago, I sat in a hospital in Leeds, Yorkshire, discussing with the parents of one of my young patients their high-dose chemotherapy treatment, including the risks of severe infection, liver and lung problems. “And,” I added as an aside, “there’s a chance of mucositis, which is a sore mouth, like a mouth ulcer.”
Three weeks later, and the child could hardly open their mouth—with lips cracked and bleeding, spitting out small pieces of the lining of their mouth, unable to eat or even swallow their own saliva. The lack of attention I had paid to mucositis up to that point struck me hard. And back then, there was very little we could do to prevent or treat it.
POGO Guidelines Offer New Approaches to Mucositis Care
Fast forward to mid-2020s when the POGO Clinical Practice Guideline update to Prevention of oral and oralpharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients summarized the most effective—and importantly the ineffective—therapies and approaches to prevent and treat mucositis in children and young people.
The POGO guideline gave us some new approaches to try, and, as it was an extremely well-produced and high-quality international guideline, the leverage to kick some of these approaches into action.
Why is it important that the guideline marks out ineffective treatments?
1) There's the hassle of taking medicines when they don't do anything.
2) There's the side effects, including stinging and bad tastes.
3) There's the unnecessary costs to the health service.
Slushies Bring New Meaning to Cold Comfort
One approach suggested in the guideline was "cryotherapy." You might have heard about cryotherapy for freezing off veruccas (warts) on your feet, or maybe with respect to Walt Disney freezing his body after death, but the phrase just means "treating with cold." In the case of mucositis prevention, this means the patient holding ice chips in their mouth. It's meant to reduce the amount of blood flowing to the delicate layers just inside the mouth, and so reduce the amount of chemo passing there to cause damage. In the UK, we struggled with the technical troubles of how to exactly procure, store and regulate popsicles within our hospital system, but this has been spectacularly and tastily overcome at McMaster Children’s Hospital in Hamilton, Ontario, with an in-unit slushie machine. Choosing which slushy you can have with chemo seems much more appealing than holding an ice cube in your mouth until it melts!
Shining a Red Light on Healing
The other main approach in the guideline was photobiomodulation. This is the use of a special wavelength of red (or infra-red) light to encourage the cells of the mouth lining to heal faster. Working with a hugely enthusiastic pair of dentists, and in collaboration with our local hospital charity, we acquired an LED-based photobiomodulation system. We put together detailed information on how to use it, how to clean it, and (after a beautiful bit of co-design and qualitative research from Dr. Claudia Heggie), a film made with young patients to explain it.
Now, despite my slight incredulity that shining what looks like a fancy red torch on someone would make them feel better, we use it frequently. We’ve massively reduced the severity of mucositis in our transplant unit and reduced the numbers of patients who've needed TPN (all your “food” fed through your central line). We’ve had patients travel from long distances to get some red light magic to feel better. We’ve seen requests from around the country asking how other units in the UK can get it going. Which makes us sound great, but it should be noted that this only got going because the POGO guidelines were there. Not wishy washy “expert” statements from the manufacturers of these devices, but guidelines with solidity and seriously interrogated evidence. This quality of document helps us persuade the administrative teams who need to control the finances of our hospitals that the intervention is truly likely to help our patients, and maybe even save money.
POGO’s Impact Immeasurable
These guidelines, the creation of a team based in Ontario, has spread good things much, much further. POGO, please listen to me, as a “come from away”: your work has power. POGO should be extremely proud of the guidelines they develop, nurture, help to create and support the uptake of. The impact they have around the world is immeasurable.
By Bob Phillips, BMBCh, PhD
Professor of Pediatric Oncology and Director, Candlelighters Supportive Care Centre,
University of York/Hull-York Medical School, UK
Dr. Bob Phillips is a Senior Academic at the Centre for Research and Dissemination and Hull York Medical School and an Honorary Consultant in Pediatric/ Teenage-Young Adult Oncology at Leeds Children's Hospital. Bob is a respected global leader in supportive care management. He spoke at the 2023 POGO Symposium on Childhood Cancer.